Leerink Partners Rates REGENXBIO (RGNX) buy, $18 Price Target

Leerink Partners Maintains Bullish Stance on REGENXBIO

Analyst Mani Foroohar of Leerink Partners reiterated a buy rating and an $18.00 price target for REGENXBIO Inc. (RGNX) on June 22, 2026. The move comes as the biotechnology firm continues to advance its pipeline of gene therapies. With the stock priced at $7.80 during the session on Monday, the analyst's target suggests a potential climb of more than 100% if the company meets those valuation expectations.

Analysts Set New Price Targets

Several other investment firms have recently updated their views on REGENXBIO. On October 5, 2026, Mizuho initiated coverage with an outperform rating and a $22.00 price target. Earlier, on August 25, 2026, Baird maintained an outperform rating but lowered its price target to $29.00 from $32.00, while HC Wainwright & Co. lowered its own target to $21.00 from $23.00 while keeping a buy rating. Barclays took a more cautious approach on August 7, 2026, downgrading the stock to equal-weight with a $12.00 price target. Overall, the consensus among 11 analysts remains positive, with a mean price target of $23.73.

REGENXBIO Stock Performance and Market Position

The stock was recently trading at $7.80, which is toward the lower end of its 52-week range of $5.46 to $16.19. The current price sits below both the 50-day moving average of $9.91 and the 200-day moving average of $10.13. This technical positioning suggests the stock has faced recent pressure even as analysts maintain high price targets. The company currently has a market capitalization of approximately $520.18 million.

Recent Earnings and Financial Health

REGENXBIO reported revenue of $174.48 million for its most recent fiscal period, representing a 4.06% increase compared to the prior year. However, as is common for clinical-stage biotech companies, it is not yet profitable. It reported a net margin of -112.58% and a return on equity of -137.63%. The company maintains a healthy liquidity position with a current ratio of 2.86, which helps fund its ongoing research and development. Shareholders are looking ahead to the next earnings report scheduled for November 5, 2026.

Clinical-Stage Gene Therapy Focus

REGENXBIO is a biotechnology company that creates gene therapies designed to fix genetic defects by delivering functional genes directly to cells. Its work is centered on its NAV Technology Platform, which it uses to develop treatments for serious conditions like wet age-related macular degeneration and Duchenne muscular dystrophy. The firm often collaborates with larger partners like AbbVie to bring these complex treatments through the clinical trial process. This specialized focus on high-stakes medicine is why analyst ratings and clinical trial milestones often drive significant moves in the stock price.

What to Watch at RGNX

Investors should monitor the upcoming quarterly results in November for updates on the company's cash burn and revenue from its technology licensing. While the $18.00 target from Leerink Partners shows high conviction, the wide range of targets from other firms—stretching from $10.00 to $50.00—highlights the volatility inherent in gene therapy stocks. Future clinical data readouts for its lead product candidates will likely be the primary catalysts for reaching these price targets.